Reproductive BioMedicine Online
Volume 19, Issue 5 , Pages 631-637 , November 2009

Follicular-fluid anti-Mullerian hormone concentrations are predictive of assisted reproduction outcome in PCOS patients

  • Recai Pabuccu

      Affiliations

    • Department of Obstetrics and Gynecology, Faculty of Medicine, Ufuk University, Ankara, Turkey
    • ,
  • Cemil Kaya

      Affiliations

    • Department of Obstetrics and Gynecology, Faculty of Medicine, Ufuk University, Ankara, Turkey
    • Corresponding Author InformationCorrespondence:
    • ,
  • Gamze Sinem Cağlar

      Affiliations

    • Department of Obstetrics and Gynecology, Faculty of Medicine, Ufuk University, Ankara, Turkey
    • ,
  • Efser Oztas

      Affiliations

    • Department of Obstetrics and Gynecology, Faculty of Medicine, Ufuk University, Ankara, Turkey
    • ,
  • Hakan Satiroglu

      Affiliations

    • Department of Obstetrics and Gynecology, Faculty of Medicine, Ankara University, Ankara, Turkey

Received 20 November 2008 ,Revised 28 April 2009 ,Accepted 3 June 2009.

References 

  1. Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Human Reproduction Update. 2003;9:505–514
  2. Cano F, Garcia-Velasco JA, Millet A, et al. Oocyte quality in polycystic ovaries revisited: identification of a particular subgroup of women. Journal of Assisted Reproduction and Genetics. 1997;14:254–261
  3. Chang MY, Chiang CH, Hsieh TT, et al. Use of the antral follicle count to predict the outcome of assisted reproductive technologies. Fertility and Sterility. 1998;69:505–510
  4. Cook CL, Siow Y, Brenner AG, Fallat ME. Relationship between serum Müllerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women. Fertility and Sterility. 2002;77:141–146
  5. Das M, Gillott DJ, Saridogan E, Djahanbakhch O. Anti-mullerian hormone is increased in follicular fluid from stimulated ovaries in women with polycystic ovary syndrome. Human Reproduction. 2008;23:2122–2126
  6. di Clemente N, Goxe B, Remy JJ, et al. Inhibitory effect of anti-mullerian hormone upon aromatase activity and LH receptors of granulosa cells of rat and porcine immature ovaries. Endocrine. 1994;2:553–558
  7. Dor J, Ben-Shlomo I, Levran D, et al. The relative success of gonadotropin-releasing hormone analogue, clomiphene citrate, and gonadotropin in 1,099 cycles of in-vitro fertilisation. Fertility and Sterility. 1992;58:986–990
  8. Durlinger AL, Gruijters MJ, Kramer P, et al. Anti-mullerian hormone attenuates the effects of FSH on follicle development in the Mouse ovary. Endocrinology. 2001;142:4891–4899
  9. Ebner T, Sommergruber M, Moser M, et al. Basal level of anti-Müllerian hormone is associated with oocyte quality in stimulated cycles. Human Reproduction. 2006;21:2022–2026
  10. Eldar-Geva T, Ben-Chetrit A, Spitz IM, et al. Dynamic assays of inhibin B, anti-mullerian hormone and estradiol following FSH stimulation and ovarian ultrasonography as predictors of IVF outcome. Human Reproduction. 2005;20:3178–3183
  11. Fallat ME, Siow Y, Marra M, et al. Müllerian-inhibiting substance in follicular fluid and serum: a comparison of patients with tubal factor infertility, polycystic ovary syndrome, and endometriosis. Fertility and Sterility. 1997;67:962–965
  12. Fanchin R, Lozano DHM, Frydman N, et al. Anti-Müllerian hormone concentrations in the follicular fluid of the preovulatory follicle are predictive of the implantation potential of the ensuing embryo obtained by in-vitro fertilization. Journal of Clinical Endocrinology and Metabolism. 2007;92:1796–1802
  13. Franks S, Roberts R, Hardy K. Gonadotrophin regimens and oocyte quality in women with polycystic ovary syndrome. Reproductive BioMedicine Online. 2002;6:181–184
  14. Franks S. Polycystic ovary syndrome. New England Journal of Medicine. 1995;333:853–861
  15. Guzick DS, Overstreet JW, Factor-Litvak P, et al. Sperm morphology, motility, and concentration in fertile and infertile men. New England Journal of Medicine. 2001;345:1388–1393
  16. Hazout A, Bouchard P, Seifer DB, et al. Serum antiMullerian hormone/mullerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertility and Sterility. 2004;82:1323–1329
  17. Kruger TF, Acosta AA, Simmons KF, et al. Predictive value of abnormal sperm morphology in in-vitro fertilization. Fertility and Sterility. 1988;49:112–117
  18. La Marca A, Malmusi S, Giulini S, et al. Anti-Müllerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation. Human Reproduction. 2004;19:27382741
  19. Laszlo FJMM, Banchsi LF, Broekmans FJ, et al. Predictors of poor ovarian response in in-vitro fertilization: a prospective study comparing basal markers of ovarian reserve. Fertility and Sterility. 2002;77:328–336
  20. Lekamge DN. Anti-Müllerian hormone as a predictor of IVF outcome. Reproductive BioMedicine Online. 2007;14:602–610
  21. Laven JS, Mulders AG, Visser JA, et al. Anti-Mullerian hormone serum concentration in nornoovulatory and anovulatory women of reproductive age. Journal of Clinical Endocrinology and Metabolism. 2004;89:318–323
  22. Ludwig M, Finas DF, Al-Hasani S, et al. Oocyte quality and treatment outcome in intracytoplasmic sperm injection cycles of polycystic ovarian syndrome patients. Human Reproduction. 1999;14:354–358
  23. Mulders A. IVF outcome in anovulatory infertility (WHO-group 2)-including polycystic ovary syndrome-following previous unsuccessful ovulation induction. Reproductive BioMedicine Online. 2003;7:50–58
  24. Paulson RJ, Suaer MV, Lobo RA. Embryo implantation after human in-vitro fertilization: importance of endometrial receptivity. Fertility and Sterility. 1990;53:870–874
  25. Pellicer A, Valbuena D, Cano F, et al. Lower implantation rates in high responders (evidence for an altered endocrine milieu during the preimplantation period). Fertility and Sterility. 1996;65:1190–1195
  26. Pigny P, Cortet-Rudelli C, Decanter C, et al. Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. Journal of Clinical Endocrinology and Metabolism. 2003;88:5957–5962
  27. Plachot M, Belaisch-Allart J, Mayenga JM, et al. Oocyte and embryo quality in polycystic ovary syndrome. Gynécologie, obstétrique and fertilité. 2003;31:350–354
  28. Reuss ML, Kline J, Santos R, et al. Age and the ovarian follicle pool assessed with transvaginal ultrasonography. American Journal of Obstetrics and Gynecology. 1996;174:624–627
  29. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group 2004 Revised 2003 consensus on diagnostic criteria and long-term healthy risks related to polycystic ovary syndrome. Fertility and Sterility 81, 19–25.
  30. Silberstein T, Maclaughin DT, Shai I, et al. Mullerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology. Human Reproduction. 2006;21:159–163
  31. Stubbs SA, Hardy K, Silva-Buttkus PD, et al. Anti-Mullerian hormone protein expression is reduced during development the initial stages of follicle development in human polycystic ovaries. Journal of Clinical Endocrinology and Metabolism. 2005;90:5536–5543
  32. Takahashi C, Fujito A, Kazuka M, et al. Anti-Müllerian hormone substance from follicular fluid is positively associated with success in oocyte fertilization during in-vitro fertilization. Fertility and Sterility. 2008;89:586–591
  33. Teissier M, Chable H, Paulhac S, Aubard Y. Comparison of follicle steroidogenesis from normal and polycystic ovaries in women undergoing IVF: relationship between steroid concentrations, follicle size, oocyte quality and fecundability. Human Reproduction. 2000;15:2471–2477
  34. Tesarik J, Junca AM, Hazout A, et al. Embryos with high implantation potential after intracytoplasmic sperm injection can be recognized by a simple, non-invasive examination of pronuclear morphology. Human Reproduction. 2000;15:1396–1399
  35. Valbuena D, Martin J, Pablo JL, et al. Increasing levels of estradiol are deleterious to embryonic implantation because they directly affect the embryo. Fertility and Sterility. 2001;76:962–968
  36. van der Meer M, Hompes PGA, de Boer JAM, et al. Cohort size rather than follicle-stimulating hormone threshold level determines ovarian sensitivity in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism. 1998;83:423–426
  37. Webber LJ, Stubbs S, Stark J, et al. Formation and early development of follicles in the polycystic ovary. Lancet. 2003;362:1017–1021
  38. Weenen C, Laven JS, Von Bergh AR, et al. Anti-mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Molecular Human Reproduction. 2004;10:77–83
  39. World Health Organization 1999 Laboratory Manual for the Examination of Human Semen and Sperm–Cervical Mucus Interaction 4th edn. Cambridge University Press, Cambridge.

 Dr Recai Pabuccu obtained his medical degree in 1975 from Istanbul University Faculty of Medicine, Turkey. After he completed his obstetrics and gynaecology residency, he worked as a clinical fellow in Reproductive Endocrinology and Infertility at the University of British Colombia, Canada. He has published more than forty articles in the field of assisted reproductive technologies and reproductive surgery. Professor Pabuccu is Director of the Department of Obstetrics and Gynecology, Ufuk University, Faculty of Medicine.Dr Recai Pabuccu

PII: S1472-6483(09)00062-5

doi: 10.1016/j.rbmo.2009.06.010

Reproductive BioMedicine Online
Volume 19, Issue 5 , Pages 631-637 , November 2009

Article Tools

* Image Usage & Resolution